Cipla, a company, in India garners significant interest from investors who closely monitor its stock price. With the company’s expansion in both international markets, it becomes crucial for potential investors to grasp the trends in the Cipla share price. This understanding can prove advantageous, for those seeking growth opportunities. In this blog post, we aim to delve into the multitude of factors that impact Cipla’s stock prices and provide an overview of fluctuations that could influence investment decisions.
Cipla Share Price Graph
About the Company
Cipla was incorporated in 1935 in the name of Chemical, Industrial & Pharmaceutical Laboratories by Khwaja Abdul Hamied. He had some proprietary formula for some drugs and medicines which he donated to the company without charging any royalty. Later, in the same year, the company was named Cipla and was registered as a limited company with a paid-up capital of 6 lakhs rupees.
Currently, Cipla is a major name in the Indian drug market. It is a large-cap company belonging to the Nifty 50 group. The company has a strong global presence. 55% of its revenue comes from its business abroad. The company manufactures drugs for human and veterinary uses. It focuses on new formulations as well. Besides drugs, it has also forayed into the manufacture of bulk drugs and pesticides. In addition, it earns its revenue from the business of food and beverages, oral hygiene products, personal care products, room fresheners and detergents.
Currently, Cipla has a presence in the drug market of 170 countries. Its manufacturing units are approved by world regulatory bodies like USFDA, WHO – Canada, and UK – MHRA.
Cipla runs two institutes in the name of Cipla Cancer Palliative Care u0026amp; Training Centre and Dr K. A Hamied Institute.
Cipla has manufactured many pioneering drugs in India and abroad. Some of them are oral contraceptive pills in the name of i-Pill, CFC-free inhalers in the US and also in Europe, generic versions of drugs to treat H1N1 influenza for the local market, Touch Breast Scan (TBS) for non-evasive early-stage breast cancer detection – among many others. Through a recent deal of Rs 95 crores, Piramal Healthcare has bought the intellectual property right of the drug i-Pill.
The company has received many awards for excellence in the drug manufacturing field.
Company Financials for Analyzing Cipla Share Price
The share price of Cipla is Rs 534.75 (as of 19.06.17, 09.20 hrs.) in BSE. The market cap is Rs 43,209 crores. The face value of a share is Rs 2. The earning per share or EPS is Rs 19.87 as per the average share price of the trailing 12 months’ data. The price-over-earning ratio or P/E stands at 31.53. The Book Value per share is Rs 181.11. The price over book value ratio or P/BV is 3.46. The Dividend yield is 0.48%. The 52 weeks high price is Rs 678.45 and 52 weeks low is Rs 507.20.
The quarter ending June 2018 reported a sales figure of Rs 3845.84 crores. Other operating income stands at Rs 93.15 crores. The operating profit stands at Rs 726.37 crores. Other income stands at Rs 170.11 crores. The EBITDA is Rs 896.48 crores. The net profit stands at Rs 451.25 crores. The earning per share or EPS of this quarter stands at Rs 5.59.
Cipla Ltd. is a Large Cap company operating in the Indian pharmaceuticals and healthcare sector.
The audited report ending on 30 June 2018 reported consolidated sales of Rs 3845.84 crores which is up by 10.01% from the sales of last quarter ending on 31 March 2018 which was Rs 3495.81 crores and the total sales in this quarter has increased by 12.05% from the sales same quarter of the previous year which was Rs 3432.32 crores.
The top management of Cipla Ltd. includes Dr Y K Hamied, Dr Peter Mugyenyi, Mr Adil Zainulbhai, Mr Ashok Sinha, Mr M K Hamied, Mr S Radhakrishnan, Mr Peter Lankau, Mr Umang Vohra, Ms Naina Lal Kidwai, Ms Punita Lal, Ms Ireena Vittal and Ms Samina Vaziralli.
Cipla Ltd. has appointed M/S Walker Chandiok & Company LLP as its auditor.
As on 30 September 2018, the company has a total number of 805,227,852 shares outstanding.
The shareholding pattern of the company currently has different shareholders in the manner mentioned below.
- The promoters and promoter group of the company hold 117,803,409 nos of shares which is equivalent to 14.63% of total shares.
- The foreign institutions or FIIs hold 206,082,337 nos of shares amounting to 25.59% of total shares.
- The foreign promoters hold 177,682,187 nos of shares or 22.07% of shares.
- Others also hold 61,453,997 nos or shares or 7.63% of total shares.
- The nationalised banks and also mutual funds together hold 88,369,547 nos of shares or 10.97% of total shares.
- Moreover, other financial institutions hold 22,816,615 nos of shares amounting to 2.83% of total shares.
- The general public also holds 130,088,285 nos of shares which is equivalent to 16.16% of total shares.
- In addition, a total number of 921,485 nos shares which are equivalent to 0.11% of total shares are subscribed to GDR.
Final Thoughts about Cipla Share Price
Overall, Cipla’s share price performance is indicative of its strong financial fundamentals. Its level of profitability over the past several years continues to be impressive. It also has enabled them to remain an attractive investment in India’s pharmaceutical sector. In conclusion, with a diversified portfolio of products, an established presence in multiple global markets and emerging growth opportunities, investors should strongly consider including Cipla stocks as part of their portfolios for long-term gains.